Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 29, 2026
Why Is Coastal Financial Corporation (CCB) Stock Down -16.22% Today?

Why Is Coastal Financial Corporation (CCB) Stock Down -16.22% Today?

Key Takeaways

  • Coastal Financial Corporation (CCB) shares fell about 16.2% to roughly $37.55, down from a prior close of $44.82.
  • The selloff followed Valley National Bancorp's agreement to acquire Bluevine, a key fintech partner of Coastal's Banking-as-a-Service (BaaS) division, CCBX.
  • The deal removes a source of expected transaction-fee growth and puts roughly $447 million of Bluevine-linked deposits in question.
  • Analysts including Keefe, Bruyette & Woods and Raymond James argued the drop overstates the actual earnings impact, with both firms maintaining Outperform ratings.
  • The decline also reflects broader negative sentiment toward BaaS-focused bank sponsors, compounding an already weak year for the stock.

Opening Summary

Coastal Financial Corporation (CCB), an Everett, Washington-based bank holding company that operates Coastal Community Bank and its fintech-focused CCBX Banking-as-a-Service platform, saw its stock plunge in Monday's session. Shares fell about 16.22% to approximately $37.55, down from a prior close of $44.82, in a sharp, volume-driven move that made the stock one of the day's notable decliners among regional and BaaS-oriented banks.

The immediate catalyst was the disclosure that Valley National Bancorp (VLY) had signed a definitive agreement to acquire Bluevine, a fast-growing fintech that has been a meaningful deposit and transaction-fee partner for Coastal's CCBX segment. Investors sold the stock on concern that losing this relationship removes a key leg of the company's growth narrative.

Bluevine Acquisition by Valley National Removes a Growth Driver

The central driver behind the selloff was Valley National Bancorp's agreement to buy Bluevine, a fintech partner linked to Coastal's CCBX division. Coastal's balance sheet held approximately $447 million in Bluevine-related deposits as of September 25, and the relationship had been viewed by investors as a key source of future transaction-fee and deposit growth for the BaaS business.

Markets reacted negatively because the acquisition raises questions about how much of that deposit base and associated fee income Coastal can retain. Valley National has signaled expectations to onboard deposits around mid-2027 following the deal's close, which would effectively remove a significant revenue and growth contributor from Coastal's platform. Coastal has said it does not expect a material adverse impact on its liquidity or funding profile, citing alternative funding sources and 22 active CCBX partnerships as of June 30, but the market nonetheless repriced the stock sharply lower.

Analyst Reaction: A Move Viewed as an Overreaction

Several sell-side firms pushed back on the magnitude of the decline, arguing that the drop exaggerated the likely earnings impact. Keefe, Bruyette & Woods said the dip "exaggerates" the probable earnings effect of losing Bluevine and described it as reflective of extremely negative sentiment around BaaS bank sponsors, while maintaining an Outperform rating. Raymond James similarly retained an Outperform rating, estimating the loss of Bluevine deposits could reduce annualized earnings per share by roughly 22 to 52 cents.

The skeptical-but-constructive analyst tone did little to stem the selling pressure, however, as investors focused on the removal of a high-growth fintech relationship that had underpinned part of Coastal's premium valuation. The stock's depressed price-to-sales multiple relative to its own history underscores how much growth expectations have already been written down.

Market Context and Trading Activity

Trading volume surged well above normal, with intraday activity climbing past 400,000 shares compared with a daily average of roughly 240,000, signaling broad-based selling rather than a single-order-driven move. The stock traded as low as the mid-$35 range during the session before stabilizing near $37.55.

The decline was consistent with a sector-wide drag on BaaS and fintech-partnership bank sponsors, a niche that has faced heightened investor skepticism over regulatory scrutiny and the durability of fintech partnerships. While the broader market and major bank indices did not move nearly as dramatically, Coastal's outsized exposure to a single high-profile partner left it far more vulnerable to the Bluevine news. The stock also remains well below its 50-day and 200-day moving averages, reflecting an extended technical downtrend.

What Comes Next for CCB

Investors will be watching Coastal's third-quarter earnings, where management has said it plans to provide additional detail on the Bluevine transaction's impact. Key areas of focus include the pace at which Bluevine-linked deposits migrate away, the company's ability to redeploy liquidity and replace lost fee income, and progress onboarding new CCBX partners.

The company faces meaningful uncertainty around the timing and magnitude of any revenue shortfall, and sentiment toward BaaS bank sponsors remains fragile. Risks include further partner attrition, regulatory changes affecting the BaaS model, and ongoing profitability challenges. On the other side, Coastal retains a diversified partnership base and alternative funding flexibility, which could limit the financial damage if execution stays on track.

Trending AI Robots

For traders seeking a more systematic approach to volatile situations like this, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, giving users a way to explore data-driven approaches to the market. Explore the Trending AI Robots to see which strategies are currently leading.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CCB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CCB's Stochastic Oscillator is remaining in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CCB's RSI Oscillator exited the oversold zone, 14 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 58%.

Following a +3.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCB advanced for three days, in 228 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

CCB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CCB as a result. In 57 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 65%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

The Aroon Indicator for CCB entered a downward trend on September 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 26 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.478) is normal, around the industry mean (1.331). P/E Ratio (13.754) is within average values for comparable stocks, (24.189). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (1.186). CCB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). CCB's P/S Ratio (1.520) is slightly lower than the industry average of (3.749).

The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CCB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock worse than average.

The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Itau Unibanco Banco Holding SA (NYSE:ITUB), US Bancorp (NYSE:USB), PNC Financial Services Group (NYSE:PNC), Deutsche Bank Aktiengesellschaft (NYSE:DB), Banco Bradesco SA (NYSE:BBD), Huntington Bancshares (NASDAQ:HBAN), Regions Financial Corp (NYSE:RF), KeyCorp (NYSE:KEY).

Industry description

Regional banks have a smaller reach than major banks, and cater mostly to one region of a country, such as a state or within a group of states. They offer services often similar – albeit with some limitations/smaller scale – compared to major banks. Taking deposits, making loans, mortgages, leases, credit cards , fund management, insurance and investment banking. SunTrust Banks, State Street Corp., M&T Bank Corp. are some examples of U.S. regional banks.

Market Cap

The average market capitalization across the Regional Banks Industry is 6.19B. The market cap for tickers in the group ranges from 22.65 to 173.31B. DBSDY holds the highest valuation in this group at 173.31B. The lowest valued company is VLYPP at 22.65.

High and low price notable news

The average weekly price growth across all stocks in the Regional Banks Industry was -2%. For the same Industry, the average monthly price growth was -2%, and the average quarterly price growth was 12%. ASBH experienced the highest price growth at 4%, while BAFN experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Regional Banks Industry was -36%. For the same stocks of the Industry, the average monthly volume growth was 8% and the average quarterly volume growth was 2%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 51
Price Growth Rating: 48
SMR Rating: 38
Profit Risk Rating: 57
Seasonality Score: -17 (-100 ... +100)
View a ticker or compare two or three
CCB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a regional bank

Industry RegionalBanks

Industry
Regional Banks
Address
5415 Evergreen Way
Phone
+1 425 257-9000
Employees
483
Web
https://www.coastalbank.com
Interact to see
Advertisement
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.
Shares of GSAT are surging approximately +15% intraday on March 25, 2026, following a prior session close of $61.09. The primary catalyst is a fresh analyst note from Scotiabank highlighting Globalstar's direct-to-device satellite connectivity bypassing cellular towers — most notably in Mexico — reinforcing the company's next-generation infrastructure thesis.
Shares of ADMA are declining approximately 12% in Wednesday's session, extending a steep two-day selloff. The primary catalyst is a short-seller research report published by Culper Research on March 24, 2026, alleging that ADMA engaged in channel stuffing to artificially inflate revenue growth.
Honeywell International (HON) and TransDigm Group (TDG) are prominent players in the aerospace and industrials sector, benefiting from rising air travel demand, defense spending, and aftermarket services. This stock comparison evaluates their business models, recent performance, and market positioning to help traders and investors assess relative strengths in the current environment. With global aviation recovery and geopolitical tensions supporting sector tailwinds, professionals seeking exposure to aerospace growth versus diversified industrials stability will find these insights relevant for portfolio decisions and relative performance analysis.
PL shares are surging approximately +15% in Wednesday's session, trading near $35.89, pushing back toward the stock's 52-week high of $36.28 set on March 20, 2026. Primary catalyst: Continued momentum from a blockbuster Q4 fiscal 2026 earnings report delivered March 19, which sent revenue 41% higher year-over-year to $86.8 million, well above the $78 million Wall Street consensus.
ASTS shares surged approximately +11.00% in active intraday trading on March 25, 2026, moving from a prior close of $86.98 to approximately $96.55. The primary driver is a broad space sector rally fueled by renewed SpaceX IPO speculation, lifting satellite and space-related equities across the board.
FUBO shares are set to open about 12% lower in Wednesday’s premarket session after closing the prior day at roughly $12.02. The decline follows a strong multi-week rally powered by balance-sheet news, including the repurchase of $140.2 million of 2026 convertible notes and improving profitability trends.
One & One Green Technologies Inc. (YDDL) shares are indicated down about 13% in Wednesday’s premarket session after closing the prior regular session at $12.00. The stock had just surged 15.6% in the latest completed session, jumping from a prior close of $10.38 to $12.00, leaving it vulnerable to swift profit‑taking and volatility.
AVXL shares are indicated down about 33% in Wednesday’s premarket session, after closing the prior regular session at $4.19. The slide follows a recent drop triggered by a wider‑than‑expected fourth‑quarter loss and ongoing questions about the company’s late‑stage neurology pipeline.
AUGO shares are trading roughly 9% higher in Wednesday action, moving from a prior close of $66.42 to around $72.40 intraday. The stock’s advance extends a powerful year-long rally underpinned by record 2025 production, surging Adjusted EBITDA, and a recently declared cash dividend of $0.66 per share.
NAVN shares are surging approximately +25% in premarket trading on March 26, 2026, following a blockbuster earnings report released after the close of the prior session. Primary catalyst: Q4 fiscal year 2026 results delivered a significant beat — revenue of $178 million rose 35% year-over-year, surpassing analyst forecasts by nearly 10%.
OLPX surged approximately +50.38% in premarket trading on March 26, 2026, from a previous close of $1.33 to approximately $2.00, with an intraday premarket high of $2.03. The primary catalyst is a definitive acquisition agreement by German consumer goods giant Henkel AG to purchase Olaplex for $2.06 per share in an all-cash deal, valuing the company at approximately $1.4 billion.
TASK shares are down approximately -36% in premarket trading on March 26, 2026, the stock's official ex-dividend date for its special $3.65 per share cash dividend. The $3.65 special cash dividend — exceeding 25% of the stock's pre-ex-div market value — triggered a mandatory Nasdaq-prescribed price adjustment on today's open.
MLKN shares are down approximately 18.90% in premarket trading on March 26, 2026, falling to $15.70 from the prior session's close of $19.36. The primary catalyst is a double miss on both earnings and revenue in the company's fiscal Q3 2026 report released after the close on March 25.
Wave Life Sciences (WVE) shares are tumbling approximately 51% in premarket trading on March 26, 2026, from a prior close of $12.30 to approximately $6.03. The primary catalyst is the release of highly anticipated INLIGHT Phase 1 clinical data for WVE-007, the company's investigational INHBE GalNAc-siRNA obesity treatment, with results falling materially short of investor expectations.
APP is trading approximately 6% lower in premarket trading on March 26, 2026, extending a multi-session losing streak. The prior regular-session close (March 25, 2026) stood at $435.91, itself already down 5.02% from the day before, making the premarket slide a continuation of accelerating selling pressure.
KOD shares surged approximately +50% in premarket trading on Thursday, March 26, 2026, from a prior closing price of $22.75 to approximately $34.13. The primary catalyst is a landmark readout: the GLOW2 Phase 3 trial of Zenkuda (tarcocimab tedromer) in diabetic retinopathy met its primary endpoint with overwhelming statistical significance.
Why Is Coastal Financial Corporation (CCB) Stock Down -16.22% Today?